TransEnterix, Inc. Announces Appointment of Interim Chief Financial Officer
02 Enero 2020 - 3:05PM
Business Wire
TransEnterix, Inc. (NYSE American:TRXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to improve minimally invasive surgery, today announced
that Brett Farabaugh has joined as interim Chief Financial Officer,
effective January 2, 2020, replacing Joe Slattery who retired
December 31, 2019, as previously announced.
“We are very excited to have Brett join the TransEnterix team.
He brings a wealth of experience providing financial leadership to
high growth healthcare and technology companies,” said Anthony
Fernando, TransEnterix President and Chief Executive Officer. “I
believe Brett’s in depth knowledge of the medical device industry
and his background of successfully guiding innovative companies
will be very valuable during this critical period as we focus on
taking the actions needed to implement changes in our commercial
strategy that I believe will drive shareholder value.”
Mr. Farabaugh has served as CFO of Tryton Medical, Inc., a
developer of coronary stents based in Durham, North Carolina since
August 2008, and as CEO of Tryton Medical since August 2019. Prior
to Tryton Medical, Mr. Farabaugh served as CFO of Strikeiron, Inc.,
a high-growth information technology company, from 2006-2008, as
Vice President of Finance for Icoria, Inc. (formerly Paradigm
Genetics, Inc.), a biotechnology company, from 2004-2006. Mr.
Farabaugh also held various roles at Nuada Pharmaceuticals and
PricewaterhouseCoopers LLP. Mr. Farabaugh holds a B.S. in Commerce
with a concentration in Accounting from the University of Virginia
and is a licenced CPA.
About TransEnterix
TransEnterix is a medical device company that is digitizing the
interface between the surgeon and the patient to improve minimally
invasive surgery by addressing the clinical and economic challenges
associated with current laparoscopic and robotic options in today's
value-based healthcare environment. The Company is focused on the
commercialization of the Senhance Surgical System, which digitizes
laparoscopic minimally invasive surgery. The system allows for
robotic precision, haptic feedback, surgeon camera control via eye
sensing and improved ergonomics while offering responsible
economics. The Senhance Surgical System is available for sale in
the US, the EU, Japan and select other countries. For more
information, visit www.transenterix.com.
Forward-Looking Statements
This press release includes statements relating to the Brett
Farabaugh’s appointment as Interim Chief Financial Officer. These
statements and other statements regarding our future plans and
goals constitute "forward looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and are intended to qualify for
the safe harbor from liability established by the Private
Securities Litigation Reform Act of 1995. Such statements are
subject to risks and uncertainties that are often difficult to
predict, are beyond our control and which may cause results to
differ materially from expectations and include whether Mr.
Farabaugh’s in depth knowledge of the medical device industry and
his background of successfully guiding innovative companies will be
very valuable to implement changes in our commercial strategy and
drive shareholder value. For a discussion of the risks and
uncertainties associated with TransEnterix's business, please
review our filings with the Securities and Exchange Commission
(SEC), including our Annual Report on Form 10-K for the year ended
December 31, 2018, filed with the SEC on February 27, 2019 and our
other filings we make with the SEC. You are cautioned not to place
undue reliance on these forward looking statements, which are based
on our expectations as of the date of this press release and speak
only as of the origination date of this press release. We undertake
no obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200102005487/en/
For TransEnterix, Inc. Investor Contact: Mark Klausner, +1
443-213-0501 invest@transenterix.com or Media Contact: Terri
Clevenger, +1 203-682-8297 terri.clevenger@icrinc.com
TransEnterix (AMEX:TRXC)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
TransEnterix (AMEX:TRXC)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024